S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

$0.58
+0.03 (+5.46%)
(As of 03/1/2024 ET)
Today's Range
$0.53
$0.58
50-Day Range
$0.41
$0.68
52-Week Range
$0.36
$2.92
Volume
663,053 shs
Average Volume
271,615 shs
Market Capitalization
$15.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

BioCardia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
589.9% Upside
$4.00 Price Target
Short Interest
Healthy
2.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of BioCardia in the last 14 days
Based on 3 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Decreasing
From ($0.52) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

Medical Sector

703rd out of 951 stocks

Biological Products, Except Diagnostic Industry

113th out of 157 stocks


BCDA stock logo

About BioCardia Stock (NASDAQ:BCDA)

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BCDA Stock Price History

BCDA Stock News Headlines

BCDA Mar 2024 1.500 call
BCDA Aug 2024 0.500 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
BCDA Mar 2024 0.500 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Positive Signs As Multiple Insiders Buy BioCardia Stock
See More Headlines
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/02/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCDA
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+589.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-11,910,000.00
Net Margins
-2,197.72%
Pretax Margin
-2,197.72%

Debt

Sales & Book Value

Annual Sales
$1.35 million
Book Value
$0.24 per share

Miscellaneous

Free Float
19,721,000
Market Cap
$15.02 million
Optionable
Optionable
Beta
1.50
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














BCDA Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCardia stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCDA shares.
View BCDA analyst ratings
or view top-rated stocks.

What is BioCardia's stock price target for 2024?

2 brokerages have issued twelve-month price targets for BioCardia's shares. Their BCDA share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 589.9% from the stock's current price.
View analysts price targets for BCDA
or view top-rated stocks among Wall Street analysts.

How have BCDA shares performed in 2024?

BioCardia's stock was trading at $0.6642 at the beginning of 2024. Since then, BCDA stock has decreased by 12.7% and is now trading at $0.5798.
View the best growth stocks for 2024 here
.

Are investors shorting BioCardia?

BioCardia saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 297,600 shares, an increase of 84.2% from the January 31st total of 161,600 shares. Based on an average daily volume of 299,700 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.5% of the company's shares are short sold.
View BioCardia's Short Interest
.

When is BioCardia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BCDA earnings forecast
.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. BioCardia had a negative net margin of 2,197.72% and a negative trailing twelve-month return on equity of 645.14%. During the same period in the previous year, the business earned ($0.30) earnings per share.

When did BioCardia's stock split?

BioCardia's stock reverse split before market open on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and

When did BioCardia IPO?

(BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

Who are BioCardia's major shareholders?

BioCardia's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.16%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Mcclung, Peter Altman and Phillip Md Et Al Frost.
View institutional ownership trends
.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDA) was last updated on 3/3/2024 by MarketBeat.com Staff